GlassScriptPhysician profile
Emily Archbald
NPI 1366647026
$8,457.11
in general payments reported to CMS, 2019-2025
29 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $535 · 2021: $935 · 2022: $1,377 · 2023: $1,495 · 2024: $1,594 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.26 |
| Education | $111.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,326.90 | 2019-2025 | |
| Abbvie INC. | $1,302.58 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $1,219.90 | 2019-2025 | |
| Genzyme Corporation | $778.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $668.38 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $602.43 | 2019-2025 | Tremfya |
| Ucb, INC. | $576.97 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $253.41 | 2019-2025 | Nemluvio, Epsolay, Aklief |
| Arcutis Biotherapeutics, INC. | $243.78 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $214.15 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $202.17 | 2019-2023 | Siliq |
| Dermavant Sciences, INC. | $169.70 | 2023-2024 | Vtama |
| Leo Pharma INC. | $167.16 | 2019-2024 | Adbry |
| Dermira, INC. | $121.58 | 2019 | |
| Janssen Scientific Affairs, LLC | $120.77 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $84.25 | 2024 | Opzelura |
| Mayne Pharma Commercial LLC | $72.58 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $70.57 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $61.94 | 2019-2024 | |
| Lilly USA, LLC | $44.82 | 2021-2024 | Zepbound, Taltz, Olumiant |
| Organon LLC | $29.78 | 2025 | Vtama |
| Botanix Sb INC | $23.88 | 2025 | Sofdra |
| Almirall LLC | $23.07 | 2019 | |
| Verrica Pharmaceuticals INC. | $21.03 | 2025 | Ycanth |
| Amgen INC. | $17.58 | 2024 | Otezla |
| Aclaris Therapeutics, INC. | $14.51 | 2019 | |
| Merck Sharp & Dohme LLC | $10.85 | 2019 | |
| Biofrontera INC. | $9.45 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Prugen, INC. Pharmaceuticals | $4.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Archbald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.